 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Review, Journal: Advances and Challenges in the Pursuit of Disease-Modifying Osteoarthritis Drugs: A Review of 2010-2024 Clinical Trials. (Pubmed Central) - Feb 26, 2025
Eleven DMOAD candidates are reviewed and critically analyzed for their potential benefit in OA treatment-Lorecivivint (SM04690), TissueGene-C, Cindunistat (SD-6010), Sprifermin, UBX0101, TPX-100, GLPG1972/S201086, Lutikizumab (ABT-981), SAR113945, MIV-711, and LNA043-and relevant challenges to their development are discussed. Six DMOADs have demonstrated statistically significant evidence of a structural or symptomatic benefit without major safety concerns in phase II and III randomized controlled trials post-2010.
- ||| LNA043 / Novartis, Ilaris (canakinumab) / Novartis
Trial termination: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov) - Aug 12, 2024
P2, N=23, Terminated, Sponsor: Novartis Pharmaceuticals
Six DMOADs have demonstrated statistically significant evidence of a structural or symptomatic benefit without major safety concerns in phase II and III randomized controlled trials post-2010. Completed --> Terminated; Sponsor Decision
- || LNA043 / Novartis, Ilaris (canakinumab) / Novartis
Trial completion: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov) - Jul 23, 2024
P2, N=23, Completed, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated; Sponsor Decision Active, not recruiting --> Completed
- ||| LNA043 / Novartis, Ilaris (canakinumab) / Novartis
Enrollment closed, Enrollment change: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov) - Apr 23, 2024
P2, N=24, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=138 --> 24
- || LNA043 / Novartis, Ilaris (canakinumab) / Novartis
Trial completion date, Trial primary completion date: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov) - Jan 23, 2024
P2, N=138, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=138 --> 24 Trial completion date: Oct 2025 --> Jun 2024 | Trial primary completion date: Oct 2025 --> Jun 2024
- |||| LNA043 / Novartis
Enrollment open: ONWARDS: Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - Aug 31, 2023
P2, N=550, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Oct 2025 --> Jun 2024 | Trial primary completion date: Oct 2025 --> Jun 2024 Active, not recruiting --> Recruiting
- || LNA043 / Novartis, Ilaris (canakinumab) / Novartis
Trial completion date, Trial primary completion date: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov) - May 16, 2023
P2, N=138, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Apr 2025 --> Oct 2025
- ||| LNA043 / Novartis
Enrollment closed: ONWARDS: Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - Mar 13, 2023
P2, N=581, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Apr 2025 --> Oct 2025 Recruiting --> Active, not recruiting
- || LNA043 / Novartis
Clinical, P1 data, Journal: Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial. (Pubmed Central) - Dec 2, 2022
P1, P2
Post-hoc transcriptomics profiling of cartilage revealed that a single LNA043 injection reverses the OA transcriptome signature over at least 21 d, inducing the expression of hyaline cartilage matrix components and anabolic signaling pathways, while suppressing mediators of OA progression. LNA043 is a novel disease-modifying OA drug candidate that is currently in a phase 2b trial ( NCT04864392 ) in patients with knee OA.
- || LNA043 / Novartis, Ilaris (canakinumab) / Novartis
Trial completion date, Trial primary completion date: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov) - Nov 3, 2022
P2, N=138, Recruiting, Sponsor: Novartis Pharmaceuticals
LNA043 is a novel disease-modifying OA drug candidate that is currently in a phase 2b trial ( NCT04864392 ) in patients with knee OA. Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
- ||| LNA043 / Novartis
Trial completion: Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis. (clinicaltrials.gov) - Oct 6, 2022
P2, N=142, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025 Active, not recruiting --> Completed
- LNA043 / Novartis
CARTILAGE REGENERATION AFTER TREATMENT WITH LNA043, A NOVEL DISEASE-MODIFYING OSTEOARTHRITIS DRUG CANDIDATE: RESULTS FROM AN IMAGING-BASED PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH FOCAL ARTICULAR CARTILAGE LESIONS IN THE KNEE () - Apr 29, 2022 - Abstract #OARSI2022OARSI_414;
P2
A previous proof-of-mechanism study focussed on imaging using 7 Tesla magnetic resonance imaging (MRI) to show the formation of hyaline-like tissue after a single injection of 20 mg LNA04. The aim of this study is to non-invasively evaluate the chondro-regenerative capacity of multiple intra-articular (i.a.) injections of LNA043 in patients with articular cartilage lesions in the knee (NCT03275064).
- LNA043 / Novartis
LNA043 A NOVEL CANDIDATE FOR OSTEOARTHRITIS TREATMENT INDUCES CARTILAGE REGENERATION AND REVERSES THE OSTEOARTHRITIS TRANSCRIPTOME () - Apr 29, 2022 - Abstract #OARSI2022OARSI_215;
Using a phenotypic screen, we discovered LNA043, a derivative of the angiopoietin-like 3 (ANGPTL3) protein and confirmed that it promotes chondrogenesis in vitro and cartilage regeneration in vivo. The mechanisms-of-action (MoA) of LNA043 was characterized by a transcriptomics analysis of OA cartilage from LNA043-treated patients and by mechanistic molecular assays.
- || LNA043 / Novartis, Ilaris (canakinumab) / Novartis
Trial completion date, Trial initiation date, Trial primary completion date: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov) - Mar 2, 2022
P2, N=138, Recruiting, Sponsor: Novartis Pharmaceuticals
The mechanisms-of-action (MoA) of LNA043 was characterized by a transcriptomics analysis of OA cartilage from LNA043-treated patients and by mechanistic molecular assays. Trial completion date: Dec 2023 --> Apr 2024 | Initiation date: Jan 2021 --> Aug 2021 | Trial primary completion date: Dec 2023 --> Apr 2024
- || LNA043 / Novartis, Ilaris (canakinumab) / Novartis
Trial completion date, Trial primary completion date: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov) - Feb 8, 2022
P2, N=138, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2023 --> Apr 2024 | Initiation date: Jan 2021 --> Aug 2021 | Trial primary completion date: Dec 2023 --> Apr 2024 Trial completion date: May 2024 --> Dec 2023 | Trial primary completion date: May 2024 --> Dec 2023
- || LNA043 / Novartis
Trial completion date, Trial primary completion date: ONWARDS: Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - Feb 1, 2022
P2, N=550, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: May 2024 --> Dec 2023 | Trial primary completion date: May 2024 --> Dec 2023 Trial completion date: Jun 2027 --> Oct 2027 | Trial primary completion date: Jun 2024 --> Nov 2024
- || LNA043 / Novartis, Ilaris (canakinumab) / Novartis
Trial initiation date: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov) - Jan 28, 2022
P2, N=138, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jun 2027 --> Oct 2027 | Trial primary completion date: Jun 2024 --> Nov 2024 Initiation date: Aug 2021 --> Jan 2021
- || LNA043 / Novartis
Enrollment closed: Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis. (clinicaltrials.gov) - Sep 17, 2021
P2, N=142, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Aug 2021 --> Jan 2021 Recruiting --> Active, not recruiting
- ||| LNA043 / Novartis
هيئة الغذاء والدواء تمنح مشروع الدواء 💉LNA043 صفة الاستعجال في مجال التهاب المفاصل (الركبة) ✅نتائج أولية من نوفارتيس @Novartis بينت بوادر تحفيز ترميم الغضروف بالحقن في المفصل https://t.co/hadxFWZIpt 🗓متوقع إجراء التجارب الإكلينيكية المرحلة الثانية قريبا https://t.co/dTKdOmSGec (Twitter) - Sep 14, 2021
- ||| LNA043 / Novartis, Ilaris (canakinumab) / Novartis
Enrollment open: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov) - Sep 5, 2021
P2, N=138, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- LNA043 / Novartis
[VIRTUAL] Anabolic effect of LNA043, a novel disease-modifying osteoarthritis drug candidate: results from an imaging-based proof-of-concept trial in patients with focal articular cartilage lesions (Room 6) - Jun 7, 2021 - Abstract #EULAR2021EULAR_4605;
- |||| LNA043 / Novartis
Enrollment open: ONWARDS: Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - Jun 3, 2021
P2, N=550, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- LNA043 / Novartis
[VIRTUAL] Regeneration of hyaline cartilage in response to a single injection of LNA043, an ANGPTL3 mimetic, in the knee of patients with a focal cartilage defect () - May 3, 2021 - Abstract #OARSI2021OARSI_282;
In a first-in-human trial (FIH), it displayed a favorable safety profile while eliciting a chondro-anabolic response as supported by the modulation of several pathways in chondrocytes involved in osteoarthritis (OA) at the RNA level. The primary objective of this trial (NCT 03334812) was to assess the efficacy of a single intra-articular (i.a.) injection of LNA043 in the regeneration of hyaline cartilage tissue at the donor site of patients undergoing autologous chondrocyte implantation (ACI).
- LNA043 / Novartis
[VIRTUAL] First-in-human trial results of LNA043, a novel cartilage regenerative treatment for osteoarthritis () - May 3, 2021 - Abstract #OARSI2021OARSI_273;
P1
Purpose: LNA043 is a modified truncated human angiopoietin-like 3 (ANGPTL3) protein identified in a phenotypic screen for inducers of chondrogenesis and cartilage repair. The primary objective of this trial (NCT02491281) was to assess safety and tolerability of single intraarticular doses of LNA043 into the knee of patients with knee osteoarthritis (OA).
- ||||| LNA043 / Novartis
New P2 trial: ONWARDS: Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - Apr 27, 2021
P2, N=550, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- LNA043 / Novartis
[VIRTUAL] ANABOLIC EFFECT OF LNA043, A NOVEL DISEASE-MODIFYING OSTEOARTHRITIS DRUG CANDIDATE: RESULTS FROM AN IMAGING-BASED PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH FOCAL ARTICULAR CARTILAGE LESIONS (Room 6) - Apr 6, 2021 - Abstract #EULAR2021EULAR_1858;
P2
Automated measurement of cartilage volume in the femoral index region was able to detect a relevant treatment effect and was found to be more sensitive than the manual segmentation method. No sign of cartilage overgrowth was observed in healthy femoral regions.
- |||| LNA043 / Novartis, Ilaris (canakinumab) / Novartis
New P2 trial: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) (clinicaltrials.gov) - Mar 23, 2021
P2, N=138, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| LNA043 / Novartis
Enrollment change, Trial completion date, Trial primary completion date: Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis. (clinicaltrials.gov) - Jan 25, 2021
P2, N=133, Recruiting, Sponsor: Novartis Pharmaceuticals
No sign of cartilage overgrowth was observed in healthy femoral regions. N=60 --> 133 | Trial completion date: Apr 2022 --> Aug 2022 | Trial primary completion date: Apr 2022 --> Aug 2022
- || LNA043 / Novartis
Trial completion: Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants (clinicaltrials.gov) - Jan 13, 2021
P1, N=12, Completed, Sponsor: Novartis Pharmaceuticals
N=60 --> 133 | Trial completion date: Apr 2022 --> Aug 2022 | Trial primary completion date: Apr 2022 --> Aug 2022 Active, not recruiting --> Completed
- || LNA043 / Novartis
Enrollment closed: Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants (clinicaltrials.gov) - Dec 9, 2020
P1, N=12, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || LNA043 / Novartis
Enrollment open: Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants (clinicaltrials.gov) - Nov 19, 2020
P1, N=12, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- LNA043 / Novartis
[VIRTUAL] LNA043, a Novel Cartilage Regenerative Treatment for Osteoarthritis: Results from a First-In-Human Trial in Patients with Knee Osteoarthritis (Feed 8) - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2182;
P1
In addition, LNA043 penetrated transiently into the articular cartilage; was quickly cleared locally and systemically; and elicited a chondroanabolic response as shown by modulating several pathways in chondrocytes involved in OA and cartilage repair at the RNA level. Further studies of LNA043 for treatment of knee OA are now in progress.
- || LNA043 / Novartis
New P1 trial: Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants (clinicaltrials.gov) - Sep 24, 2020
P1, N=12, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| LNA043 / Novartis
Enrollment open, Trial completion date, Trial primary completion date: Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis. (clinicaltrials.gov) - May 19, 2020
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Further studies of LNA043 for treatment of knee OA are now in progress. Active, not recruiting --> Recruiting | Trial completion date: Sep 2020 --> Mar 2022 | Trial primary completion date: Sep 2020 --> Mar 2022
- ||| LNA043 / Novartis
Trial termination: Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (clinicaltrials.gov) - Apr 17, 2020
P2, N=14, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting | Trial completion date: Sep 2020 --> Mar 2022 | Trial primary completion date: Sep 2020 --> Mar 2022 Completed --> Terminated; This study was terminated early based on an interim analysis of 14 subjects, which demonstrated a favorable safety and tolerability profile.
- || LNA043 / Novartis
Trial completion date, Trial primary completion date: Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis. (clinicaltrials.gov) - Oct 31, 2019
P2, N=59, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated; This study was terminated early based on an interim analysis of 14 subjects, which demonstrated a favorable safety and tolerability profile. Trial completion date: Jan 2020 --> Sep 2020 | Trial primary completion date: Jan 2020 --> Sep 2020
- | LNA043 / Novartis
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (clinicaltrials.gov) - Sep 25, 2019
P2, N=15, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jan 2020 --> Sep 2020 | Trial primary completion date: Jan 2020 --> Sep 2020 Recruiting --> Completed | N=22 --> 15 | Trial completion date: Oct 2019 --> Apr 2019 | Trial primary completion date: Oct 2019 --> Apr 2019
- | LNA043 / Novartis
Enrollment closed, Trial completion date, Trial primary completion date: Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis. (clinicaltrials.gov) - Sep 11, 2019
P2, N=59, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=22 --> 15 | Trial completion date: Oct 2019 --> Apr 2019 | Trial primary completion date: Oct 2019 --> Apr 2019 Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Jan 2020 | Trial primary completion date: Sep 2019 --> Jan 2020
- | LNA043 / Novartis
Trial completion date, Trial primary completion date: Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (clinicaltrials.gov) - Dec 19, 2018
P2, N=22, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Jan 2020 | Trial primary completion date: Sep 2019 --> Jan 2020 Trial completion date: May 2019 --> Oct 2019 | Trial primary completion date: May 2019 --> Oct 2019
- | LNA043 / Novartis
Trial completion date, Trial primary completion date: Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis. (clinicaltrials.gov) - Nov 23, 2018
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: May 2019 --> Oct 2019 | Trial primary completion date: May 2019 --> Oct 2019 Trial completion date: Dec 2018 --> Sep 2019 | Trial primary completion date: Dec 2018 --> Sep 2019
- | LNA043 / Novartis
Enrollment change: First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement (clinicaltrials.gov) - Aug 31, 2018
P1, N=28, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2018 --> Sep 2019 | Trial primary completion date: Dec 2018 --> Sep 2019 N=21 --> 28
- | LNA043 / Novartis
Trial completion date, Trial primary completion date: Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (clinicaltrials.gov) - Jul 30, 2018
P2, N=22, Recruiting, Sponsor: Novartis Pharmaceuticals
N=21 --> 28 Trial completion date: Nov 2018 --> May 2019 | Trial primary completion date: Nov 2018 --> May 2019
- | LNA043 / Novartis
Trial completion: First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement (clinicaltrials.gov) - Apr 3, 2018
P1, N=21, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Nov 2018 --> May 2019 | Trial primary completion date: Nov 2018 --> May 2019 Recruiting --> Completed
- | LNA043 / Novartis
New P2 trial: Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (clinicaltrials.gov) - Nov 7, 2017
P2, N=22, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| LNA043 / Novartis
New P2 trial: Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis. (clinicaltrials.gov) - Sep 6, 2017
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
- LNA043 / Novartis
Trial primary completion date: First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement (clinicaltrials.gov) - Aug 3, 2017
P1, N=24, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Trial primary completion date: Aug 2017 --> Dec 2017
- LNA043 / Novartis
Trial primary completion date: First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement (clinicaltrials.gov) - Mar 14, 2017
P1, N=24, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2017 --> Dec 2017 Trial primary completion date: Feb 2017 --> May 2017
- LNA043 / Novartis
Trial primary completion date: First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement (clinicaltrials.gov) - Sep 13, 2016
P1, N=24, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2017 --> May 2017 Trial primary completion date: Oct 2016 --> Jan 2017
- LNA043 / Novartis
Enrollment open: First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement (clinicaltrials.gov) - Dec 10, 2015
P1, N=24, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- LNA043 / Novartis
New P1 trial: First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement (clinicaltrials.gov) - Jul 8, 2015
P1, N=24, Not yet recruiting, Sponsor: Novartis Pharmaceuticals